ImmunoCellular Therapeutics (IMUC) Reports Q3 Loss of $0.40

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q3 EPS of ($0.40), versus ($1.58) reported last year.

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q3 EPS by 8c
• Top airline stocks to watch as fuel volatility tests sector outlook
• Perimeter Solutions SA (PRM) PT Lowered to $38 at UBS, Buy Rating Maintained Into Q3 Print